Presently, few options are available for refractory colorectal cancer (CRC). O6-methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation is a frequent and early event in CRC tumourigenesis.

Retrospective review for outcomes of IDH mutant, 1p/19q co-deleted gliomas based on initial treatment. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does not ...

Complete Title: A Phase 3, open-label, randomized 2-arm study comparing the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated ...

A phase I trial of vorinostat in combination with bevacizumab and irinotecan in recurrent glioblastoma. Background: Expected median survival is poor for patients with glioblastoma multiforme (GBM).

MGMT methylation test will be used in trial evaluating immunotherapeutic rindopepimut. CellDex Therapeutics signed an agreement with MDxHealth under which the latter’s epigenetic MGMT test will be ...